Elusys, U.S. Department of Health and Human Services infectious news

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded Elusys $14.5 million under 2009 and 2011 contracts to develop Anthim ( ETI-204) to prevent and treat anthrax infection. The company will use the funding to conduct final, expanded safety studies for IV use of Anthim, as well as a dose-escalation safety study for intramuscular use of the product. The company has now received a total of $149 million under the two BARDA contracts, which are worth up to $211 million combined. Elusys plans to begin Phase III testing of Anthim next year (see BioCentury, Aug. 9, 2010 & Sept. 12, 2011). ...